Medical tech company Enovis received a "Moderate Buy" rating with a $72.63 target price, meeting EPS and exceeding revenue estimates.

Medical tech company Enovis Co. (NYSE: ENOV) has received a "Moderate Buy" average rating from nine brokers covering it, with a 1-year target price of $72.63. The firm reported $0.50 EPS, meeting the consensus estimate, and revenue of $516M, exceeding the consensus estimate. Institutional investors hold a 98.45% stake in Enovis.

June 30, 2024
3 Articles